Sch 39304

Sch 42427 is the active entantiomer of the antifungal agent Sch 39304 which consists of Sch 42426 & Sch 42427; Sch 42426, the (S,S)-isomer, is inactive

Also Known As:

SM 8668; SM-8668; Sch 42426; Sch 42427; Sch-39304; Sch-42426; Sch-42427; genaconazole; threo-2-(2,4-difluorophenyl)-3-methylsulfonyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; 1H-1,2,4-Triazole-1-ethanol, a-(2,4-difluorophenyl)-a-(1-(methylsulfonyl)ethyl)-

Networked: 26 relevant articles (8 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - Sch 39304: 26

Related Diseases

1.	Infections 02/01/1992 - "albicans vaginal infection in hamsters, SCH 42427 p.o. " 02/01/1992 - "In a pulmonary Aspergillus flavus infection in mice, SCH 42427 p.o. " 01/01/1992 - "Excellent protection was also seen when mice were treated with a single oral dose of SCH 39304 up to 24 h prior to infection with C. " 01/01/1993 - "Following oral administration, Sch 39304 (2.5 mg kg-1, once daily, 10 days) produced a dramatic reduction in lesion scores and was 20-fold more active than FLZ; however, due to the length of time it takes for the drugs to reach the infected area of the skin and eradicate the infections, most animals remained culture positive with both drugs. " 01/01/1992 - "albicans infection model indicated that SCH 39304 is equally efficacious following either oral or intravenous administration. "
2.	Body Weight (Weight, Body) 09/01/1991 - "Optimum protection was obtained when a single dose of 10 mg of AMB per kg of body weight was combined with a fairly narrow SCH 39304 dose range. " 06/01/1990 - "We characterized the cerebrospinal fluid (CSF) penetration and pharmacokinetics of SCH-39304 in adult rhesus monkeys receiving a single oral dose of SCH-39304 (2.0 mg/kg of body weight). " 04/01/1991 - "Only SCH 39304 at 25 or 50 mg/kg of body weight per day produced 100% survival for 30 days after the 20-day treatment, although only 33% of the mice were cleared of infection. " 05/01/1990 - "A dose response protective effect was observed with SCH 39304 at 5 to 100 mg/kg of body weight per day, with 5 mg of SCH 39304 per kg per day providing activity similar to that of 100 mg of fluconazole per kg per day. " 01/01/1992 - "In normal mice, SCH 39304 (dose to reduce kidney counts by 4 log units, 0.5 mg/kg of body weight) was 3 and 200 times more active than fluconazole and ketoconazole, respectively. "
3.	Candidiasis (Moniliasis) 08/01/1990 - "SCH-39304 also was most effective in granulocytopenic rabbits with disseminated candidiasis when used for prevention or early treatment." 08/01/1990 - "Thus, SCH-39304 was comparable to treatment control regimens in prevention and early treatment of subacute disseminated candidiasis. " 08/01/1990 - "To investigate the potential use of SCH-39304 for the prevention and treatment of disseminated candidiasis in granulocytopenic patients, we studied its in vivo antifungal activity as preventive, early, and late treatments in three models (acute, subacute, and chronic) of disseminated candidiasis in persistently granulocytopenic rabbits. " 08/01/1990 - "SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits." 07/01/1989 - "Treatment of experimental candidiasis in rats with SCH 39304 and fluconazole resulted in 50% effective doses of 0.33 and 0.49 mg/kg per day, respectively. "
4.	Blastomycosis 05/01/1990 - "We conclude that SCH 39304 is effective in murine blastomycosis treatment and deserves to be evaluated in the treatment of human blastomycosis." 04/01/1991 - "SCH 39304 was clearly superior on a milligram-per-kilogram basis in acute blastomycosis, and long-term treatment of more severe blastomycosis was curative." 04/01/1991 - "In a model of established blastomycosis, used to evaluate long-term treatment of very sick or moribund mice, SCH 39304 at 50 mg/kg/day protected against death with a 96% cumulative 8-week survival. " 04/01/1991 - "SCH 39304 in the treatment of acute or established murine pulmonary blastomycosis." 05/01/1990 - "SCH 39304, a broad-spectrum azole derivative, was evaluated in an experimental mouse model of blastomycosis pneumonia. "
5.	Aspergillosis 10/01/1991 - "The efficacy of SCH 39304 (SCH) against Aspergillus fumigatus was assessed with an immunosuppressed, temporarily leukopenic rabbit model of invasive aspergillosis. " 10/01/1991 - "Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis." 06/01/1990 - "The prophylactic effect of SM-8668 was excellent against systemic candidiasis, aspergillosis, and cryptococcosis in mice. " 11/01/1992 - "Response of trichosporonosis to azoles was seen in all eight patients, although one patient died with disseminated aspergillosis while still receiving SCH 39304. "

Related Drugs and Biologics

1.	Triazoles
2.	Fluconazole (Zonal)
3.	Amphotericin B (Amphotericin)
4.	liposomal amphotericin B
5.	deoxycholate drug combination amphotericin B
6.	Antifungal Agents
7.	Sch 39304
8.	Azoles
9.	Ketoconazole (Nizoral)
10.	Interferon-gamma (Interferon, gamma)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Intravenous Administration
4.	Topical Administration
5.	Oral Administration